Today, David F. Arons, JD, Chief Executive Officer of the National Brain Tumor Society, release the following statement in regards to the nomination of Dr. Scott Gottlieb to head the U.S. Food and Drug Administration (FDA):
“After significant consideration, consultations with experts in the field, and review of testimony before the U.S. Senate Committee on Health, Education, Labor, and Pensions, the National Brain Tumor Society feels confident in offering our support of Dr. Scott Gottlieb to become the next Commissioner of the U.S. Food and Drug Administration.
As a trained medical doctor, cancer survivor, and former deputy commissioner at the FDA, we believe Dr. Gottlieb has the requisite experience to be an objective facilitator of cancer drug development, including brain tumor products. We were particularly encouraged by his focus during congressional testimony on maintaining the FDA’s ‘gold standard’ for new drug approval, as well as striking the appropriate balance between expediency, safety, and good science during the agency’s evaluation and approval activity. It was also heartening to hear Dr. Gottlieb’s support for innovative clinical trial designs as this is an area NBTS has been interested in for a number of years as a way to further biomarker-driven therapy development and learn from every patient that bravely volunteers to participate in the research process.
Finally, looking ahead we hope Dr. Gottlieb will continue to support and strengthen the FDA’s Oncology Center of Excellence, headed by Dr. Richard Pazdur and his dedicated staff, as they rigorously review applications for neuro-oncology products seeking approval and ensure that new treatments are safe and effective for brain tumor patients.”